(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia and AVC-203 for the treatment of B-cell malignancies. As per the terms of the deal, Ligand has committed up to $41 million in exchange for a mid-single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets, including AVC-201 and AVC-203, with the applicable rate determined based on the total amount ultimately funded.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。